Immunologic Factors: all 3,292 studies that test it
Page 22 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentWithdrawnNCT02470559Phase 1
- MabionCD20® Compared to MabThera® in Patients With Rheumatoid ArthritisCompletedNCT02468791Phase 3
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromeCompletedNCT02462252Phase 2
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Study of Immunotherapy in Autoantibody Positive PsychosisCompletedNCT02449746Not applicable
- Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)Status unknownNCT02447822Phase 4
- Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCompletedNCT02444546Phase 1
- Different Doses of IVIG for Kawasaki DiseaseCompletedNCT02439996Phase 3
- Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic SyndromeCompletedNCT02438982Phase 3
- Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabCompletedNCT02433522Phase 3
- Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT02427620Phase 2
- Clinical Study of CWP232291 in Relapsed or Refractory Myeloma PatientsCompletedNCT02426723Phase 1
- Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaStatus unknownNCT02423837Phase 3
- Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsWithdrawnNCT02420938Phase 2
- Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- BNHL-2015 for Children or Adolescents in ChinaActive, not recruitingNCT02405676Phase 2/3
- Transcriptome Analysis of the Peripheral Blood in CIDPStatus unknownNCT02404298Not applicable
- Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
- A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse MyelitisTerminatedNCT02398994Phase 3
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedNCT02398240Phase 2
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
- Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic SyndromeStatus unknownNCT02382575Phase 4
- B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary CirrhosisCompletedNCT02376335Phase 2
- IVIg for Demyelination in Diabetes MellitusStatus unknownNCT02372149Phase 4
- Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
- Evaluation of the Immune Restoration Potential Of LenalidomideWithdrawnNCT02371577Phase 2
- GM-CSF to Decrease ICU Acquired InfectionsCompletedNCT02361528Phase 3
- Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult PatientsStatus unknownNCT02354313Phase 3
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
- Immunotherapy and Paraneoplastic Neurological SyndromesCompletedNCT02343211Phase 2
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingNCT02334865Phase 1
- Treatment -Resistant Neovascular Age-Related Macular DegenerationCompletedNCT02332941Phase 1
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaStatus unknownNCT02325440Phase 4
- Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaStatus unknownNCT02313389Phase 3
- Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
- Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With EncephalitisCompletedNCT02308982Phase 3
- Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)CompletedNCT02304354Phase 3
- Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)CompletedNCT02303119Phase 3
- Study of Lenalidomide in Relapse/Refractory Waldenstrom MacroglobulinemiaCompletedNCT02302469Phase 1/2
- Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I StudyCompletedNCT02287558Phase 1
- An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar AtaxiasStatus unknownNCT02287064Phase 1
- Synergetic B-cell Immodulation in SLECompletedNCT02284984Phase 2
- SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompletedNCT02283775Phase 1
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- HER2-Peptide Vaccination of Patients With Solid TumorsCompletedNCT02276300Phase 1
- Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept StudyTerminatedNCT02271165Early Phase 1
- Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTStatus unknownNCT02267915Phase 2
- Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AMLTerminatedNCT02255162Phase 1
- A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis PatientsCompletedNCT02253264Phase 1
- Rituximab in Interstitial PneumonitisCompletedNCT02251964Phase 2/3
- The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate CancerCompletedNCT02250014Phase 1
- A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody DeficiencyCompletedNCT02247154Phase 4
- A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy VolunteersCompletedNCT02246855Phase 1
- Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
- B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.CompletedNCT02229942Phase 3
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasWithdrawnNCT02228512Phase 1/2
- Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeCompletedNCT02221271Phase 3
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
- STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDSCompletedNCT02215980Phase 3
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisActive, not recruitingNCT02205762Phase 2/3
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedNCT02203643Phase 2
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic AnemiaCompletedNCT02203396Phase 2
- Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
- An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism SpectrumStatus unknownNCT02199925Phase 4
- Low-dose Glucocorticoid Vasculitis Induction StudyStatus unknownNCT02198248Phase 4
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome TrialCompletedNCT02193698Phase 2
- Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)CompletedNCT02185820Phase 1/2
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
- Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and BortezomibStatus unknownNCT02158702Phase 2
- Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus RituximabCompletedNCT02157181Phase 2
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Treatment Optimization in Patients With Untreated Multiple MyelomaTerminatedNCT02145598Phase 2/3
- Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaStatus unknownNCT02142335Phase 2
- Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
- Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminatedNCT02142192Phase 2
- A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02137681Phase 3
- PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus PneumoniaeCompletedNCT02133469Not applicable
- Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+CompletedNCT02128061Phase 3
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
- A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisCompletedNCT02115997Phase 4
- Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
- Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled TrialCompletedNCT02111161Phase 2
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
- Single Dose rATG for Renal Allograft RejectionStatus unknownNCT02102854Phase 4
- Rituximab and DexaBEAM as Salvage Therapy for Relapsed LymphomaCompletedNCT02099292Phase 2